Posted on: 12 January 2024
After promising results in the treatment of depression, the CIPPRes Clinic is now focusing on anorexia, chronic pain and obsessive-compulsive disorder (OCD).
CIPPRes is a research initiative between Imperial College London and CNWL.
They are leading psychedelic research in the UK, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.
Launched in 2021, it is led by Dr David Erritzoe and Dr David Nutt, who run the clinic at St Charles Hospital.
Focused on experimental psychopharmacology, it specifically investigates the effects of psychedelics and ketamine in healthy and psychiatric populations.
The researchers use imaging methods such as PET (positron emission tomography), MRI (magnetic resonance imaging), and EEG (electroencephalography), hoping to uncover therapeutic potential and mechanisms.
They aim to be a prototype for licensed psychedelic care facilities of the future.
CIPPRes' collaborative activities allow for unique research training opportunities for trainees and other staff in CNWL and an important exchange of knowledge between academics and clinicians.